Aurobindo Pharma shares rose over 3% in Monday trading following the announcement of its subsidiary's US market entry, with the stock hitting an intraday high of ₹1,703 per share on the NSE. As per The Economic Times, the pharmaceutical company's stock was trading at ₹1,682.90, up 2.29% from the previous close of ₹1,645.30 at 1:50 PM on Monday. The strong market response reflects investor confidence in the company's strategic expansion into complex generics. Aurobindo Pharma shares have delivered a return of 41.16% year-to-date in 2026 and have gained 63.83% over the past one year, demonstrating robust investor sentiment. The company commands a market capitalisation of ₹96,721.02 crore at current market prices.
Aurobindo Pharma has successfully entered the US inhalation market with the launch of generic Advair Diskus, marking a strategic expansion of its complex generics portfolio beyond conventional oral solid formulations. The company, through its wholly owned subsidiary Lannett Company LLC, has launched the generic equivalent of Advair Diskus (fluticasone propionate and salmeterol inhalation powder) in the US in 100/50 mcg and 250/50 mcg strengths. According to Business Standard, this product is used for the treatment of asthma and chronic obstructive pulmonary disease (COPD). The launch represents the first product from the company's inhalation pipeline to reach the US market, providing a foothold in a segment where product development and manufacturing are more complex than conventional generics. As reported by Moneycontrol, the company stated that "This launch marks the first product from our inhalation pipeline to be commercialised in the US, reflecting our continued focus on expanding our portfolio of complex and differentiated inhalation products."
Aurobindo Pharma shares demonstrated strong trading activity with nearly 14 lakh equity shares valued at around ₹235 crore exchanging hands on the BSE and NSE during Monday's trading session. As per The Economic Times, the stock showed strong buying interest despite some profit-taking after the initial surge. The company's market capitalisation of ₹96,721.02 crore reflects its established position in the pharmaceutical sector. The robust trading volumes indicate significant investor interest in the company's strategic expansion into complex generics and its successful entry into the US inhalation market.
The United States Food and Drug Administration (US FDA) has closed its inspection of Unit-VI, an API manufacturing facility of Apitoria Pharma, a wholly owned subsidiary of Aurobindo Pharma, situated at E-Bonangi Village, Parawada Mandal, Anakapalli District, Andhra Pradesh. According to company reports, the inspection concluded with three observations, which are procedural in nature. The company has committed to responding to the US FDA within the stipulated timeline and will keep exchanges informed of further developments. As per multiple reports, the three observations are classified as purely procedural, with zero data integrity or compliance issues noted, indicating operational rather than systemic quality concerns. The disclosure was made under Regulation 30 of SEBI's listing regulations.
Aurobindo Pharma has multiple inhalation products under development and the Advair launch reflects its focus on expanding its portfolio of complex and differentiated inhalation products. As reported by Business Standard, inhalation products typically require specialized formulation, device and manufacturing capabilities, as well as regulatory expertise, making the segment relatively more difficult to enter but also providing generic drugmakers with opportunities to build differentiated portfolios. The move is part of the company's broader effort to strengthen its US business through complex generics, leveraging its sizable manufacturing and research and development infrastructure with more than 30 manufacturing and packaging facilities approved by major global regulatory agencies, including the USFDA. The US market remains key for Indian generic drugmakers, but pricing pressure and intense competition in conventional generics have increasingly pushed companies towards complex products.
